In contrast to large clinical trials [26,27] and meta-analyses of SGLT2i effects in CKD patients [28], in which SGLT2i treatment reduced the risk of kidney disease progression, in our cohort, Prt did not change significantly, Sur increased, and Ccr decreased significantly. The gene discussed is ABCC8; the disease is chronic kidney disease.